Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia

References

• LokenMRShahVODattilioKLCivinCIFlow cytometric analysis of bone marrow. II. Normal B lymphocyte developmentBlood1987705131613243117132
   PubMed Web of Science ®Google Scholar
• CampoESwerdlowSHHarrisNLPileriSSteinHJaffeESThe 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applicationsBlood2011117195019503221300984
   PubMed Web of Science ®Google Scholar
• CraggMSWalsheCAIvanovAOGlennieMJThe biology of CD20 and its potential as a target for mAb therapyCurr Dir Autoimmun2005814017415564720
   PubMedGoogle Scholar
• CraggMSMorganSMChanHTComplement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid raftsBlood200310131045105212393541
   PubMed Web of Science ®Google Scholar
• TadaMIshii-WatabeASuzukiTKawasakiNDevelopment of a cell-based assay measuring the activation of FcγRIIa for the characterization of therapeutic monoclonal antibodiesPLoS One201494e9578724752341
   PubMed Web of Science ®Google Scholar
• AlduaijWIvanovAHoneychurchJNovel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignanciesBlood2011117174519452921378274
   PubMed Web of Science ®Google Scholar
• AbèsRGélizéEFridmanWHTeillaudJLLong-lasting antitumor protection by anti-CD20 antibody through cellular immune responseBlood2010116692693420439625
   PubMed Web of Science ®Google Scholar
• NiederfellnerGLammensAMundiglOEpitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodiesBlood201111835836721444918
   PubMed Web of Science ®Google Scholar
• RobakTCurrent and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the artExpert Rev Hematol20147684185725249370
   PubMed Web of Science ®Google Scholar
• HerterSHertingFMundiglOPreclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft modelsMol Cancer Ther2013121020132042
   Web of Science ®Google Scholar
• AbulayhaABredanAEl EnshasyHDanielsIRituximab: modes of action, remaining dispute and future perspectiveFuture Oncol201410152481249225525856
   PubMed Web of Science ®Google Scholar
• PawluczkowyczAWBeurskensFJBeumPVBinding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab or rituximab: considerably higher levels of CDC are induced by ofatumumab than rituximabJ Immunol2009183174975819535640
   PubMed Web of Science ®Google Scholar
• MössnerEBrünkerPMoserSIncreasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicityBlood2010115224393440220194898
   PubMed Web of Science ®Google Scholar
• PatzMIsaevaPForcobNComparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cellsBr J Haematol2011152329530621155758
   PubMed Web of Science ®Google Scholar
• DalleSReslanLBesseyre de HortsTPreclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101Mol Cancer Ther201110117818521220500
   PubMed Web of Science ®Google Scholar
• KleinCLammensASchäferWEpitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional propertiesMAbs201351223323211638
   PubMed Web of Science ®Google Scholar
• BolognaLGottiEManganiniMMechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumabJ Immunol201118663762376921296976
   PubMed Web of Science ®Google Scholar
• JakMvan BochoveGGReitsEACD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101Blood2011118195178518821948297
   PubMed Web of Science ®Google Scholar
• HoneychurchJAlduaijWAzizyanMAntibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathwayBlood2012119153523353322354003
   PubMed Web of Science ®Google Scholar
• GolayJDa RoitFBolognaLGlycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximabBlood2013122203482349124106207
   PubMed Web of Science ®Google Scholar
• KernDJJamesBRBlackwellSGassnerCKleinCWeinerGJGA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is presentLeuk Lymphoma201354112500250523452151
   PubMed Web of Science ®Google Scholar
• ReslanLDalleSHerveauSPerrialEDumontetCApoptotic induction by anti-CD20 antibodies in chronic lymphocytic leukemia: comparison of rituximab and obinutuzumabLeuk Lymphoma201455118819023537278
   PubMed Web of Science ®Google Scholar
• HertingFFriessTBaderSEnhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphomaLeuk Lymphoma20145592151216024304419
   PubMed Web of Science ®Google Scholar
• American Cancer SocietyCancer Facts and Figures 2015Atlanta GAAmerican Cancer Society2015
   Google Scholar
• ZelenetzADGordonLIWierdaWGChronic lymphocytic leukemia/small lymphocytic lymphoma, version 1. 2015J Natl Compr Canc Netw201513332636225736010
   PubMed Web of Science ®Google Scholar
• WierdaWGO’BrienSWangXCharacteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatmentJ Clin Oncol200927101637164319224852
   PubMed Web of Science ®Google Scholar
• UltmannJEHymanGAGellhornAChlorambucil in treatment of chronic lymphocytic leukemia and certain lymphomasJAMA19561623178183
   Web of Science ®Google Scholar
• MontserratEAlcaláAAlonsoCA randomized trial comparing chlorambucil plus prednisone vs cyclophosphamide, melphalan, and prednisone in the treatment of chronic lymphocytic leukemia stages B and CNouv Rev Fr Hematol1988305–64294323065738
   PubMedGoogle Scholar
• HansenMMAndersenEChristensenBECHOP versus prednisolone + chlorambucil in chronic lymphocytic leukemia (CLL): preliminary results of a randomized multicenter trialNouv Rev Fr Hematol1988305–64334363065739
   PubMedGoogle Scholar
• RaphaelBAndersenJWSilberRComparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trialJ Clin Oncol1991957707762016618
   PubMed Web of Science ®Google Scholar
• KeatingMJKantarjianHO’BrienSFludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemiaJ Clin Oncol19919144491702145
   PubMed Web of Science ®Google Scholar
• ByrdJCPetersonBLMorrisonVARandomized Phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)Blood2003101161412393429
   PubMed Web of Science ®Google Scholar
• KeatingMJO’BrienSAlbitarMEarly results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemiaJ Clin Oncol200523184079408815767648
   PubMed Web of Science ®Google Scholar
• TamCSO’BrienSPlunkettWLong-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)Blood2014124203059306425281606
   PubMed Web of Science ®Google Scholar
• EichhorstBFBuschRStilgenbauerSGerman CLL Study Group (GCLLSG)First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemiaBlood2009114163382339119605849
   PubMed Web of Science ®Google Scholar
• KnaufWULissitchkovTAldaoudABendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trialBr J Haematol20121591677722861163
   PubMed Web of Science ®Google Scholar
• LinnBSLinnMWGurelLCumulative illness rating scaleJ Am Geriatr Soc19681656226265646906
   PubMed Web of Science ®Google Scholar
• GoedeVCramerPBuschRGerman CLL Study GroupInteractions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trialsHaematologica20149961095110024584349
   PubMed Web of Science ®Google Scholar
• EichhorstBFinkAMBuschRFrontline chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab shows superior efficacy in comparison to bendamustine and rituximab in previously untreated and physically fit patients with advanced CLLAmer Soc Hematol Annual Meeting Abstract192014San Francisco, CA
   Google Scholar
• SehnLHAssoulineSEStewartDAA phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignanciesBlood2012119225118512522438256
   PubMed Web of Science ®Google Scholar
• SallesGMorschhauserFLamyTPhase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patientsBlood2012119225126513222431570
   PubMed Web of Science ®Google Scholar
• SallesGAMorschhauserFSolal-CélignyPObinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN studyJ Clin Oncol201331232920292623835715
   PubMed Web of Science ®Google Scholar
• MorschhauserFACartronGThieblemontCObinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN studyJ Clin Oncol201331232912291923835718
   PubMed Web of Science ®Google Scholar
• CartronGde GuibertSDilhuydyMSObinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN studyBlood2014124142196220225143487
   PubMed Web of Science ®Google Scholar
• GoedeVFischerKBuschRObinutuzumab plus chlorambucil in patients with CLL and coexisting conditionsN Engl J Med2014370121101111024401022
   PubMed Web of Science ®Google Scholar
• PonaderSChenSSBuggyJJThe Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivoBlood20121191182118922180443
   PubMed Web of Science ®Google Scholar
• ByrdJCBrownJRO’BrienSRESONATE InvestigatorsIbrutinib versus ofatumumab in previously treated chronic lymphoid leukemiaN Engl J Med2014371321322324881631
   PubMed Web of Science ®Google Scholar
• HoellenriegelJMeadowsSASivinaMThe phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell signaling and chemokine networks in chronic lymphocytic leukemiaBlood20111183603361221803855
   PubMed Web of Science ®Google Scholar
• FurmanRRSharmanJPCoutreSEIdelalisib and rituximab in relapsed chronic lymphocytic leukemiaN Engl J Med201437011997100724450857
   PubMed Web of Science ®Google Scholar
• RaiKRPetersonBLAppelbaumFRFludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemiaN Engl J Med2000343241750175711114313
   PubMed Web of Science ®Google Scholar
• CatovskyDRichardsSMatutesEUK National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group, NCRI Chronic Lymphocytic Leukaemia Working GroupAssessment of fludarabine plus chlorambucil for patients with chronic lymphocytic leukemia (the LRF CLL4 trial): a randomized controlled trialLancet2007370958323023917658394
   PubMed Web of Science ®Google Scholar
• HillmenPSkotnickiABRobakTAlemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemiaJ Clin Oncol200725355616562317984186
   PubMed Web of Science ®Google Scholar
• CraggMSCD20 antibodies: doing the time warpBlood2011118221922021757627
   PubMed Web of Science ®Google Scholar